Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis
Status:
Completed
Trial end date:
2017-03-02
Target enrollment:
Participant gender:
Summary
Local allergic rhinitis (LAR) is relatively new disease. The question of effect of allergen
specific immunotherapy on LAR is open. The randomized, double blind placebo controlled trial
of birch subcutaneous AIT on LAR were performed in twenty eight patients. The therapy was
performed during 24 months in proportion 15 patients with AIT and 13 placebo. The primary
endpoint was decreased of symptoms medication score (SMS). Additionally monitoring serum
specific IgE, specific IgG4 and nasal specific IgE (nsIgE) to Bet v1 and parameters of safety
and quality of life were provided.